(MENAFN- America News Hour)
Key Companies Covered in the North America Sly Syndrome Market Research are Shire (Takeda Pharmaceutical Company Limited) Denali Therapeutics ArmaGen REGENXBIO Inc. Sangamo Therapeutics BioMarin Lysogene and other key market players .
The global North America Sly Syndrome Market size is projected to reach USD 4.97 billion by 2033 from USD 2.98 billion in 2023, at a CAGR of 10.4% during the forecast period .Increasing Number of Clinical Stage Candidates in R&D Pipelines of Major Players to Drive Market
CRIFAX added a report on 'North America Sly Syndrome Market, 2023-2033' to its database of market research collaterals consisting of overall market scenario with prevalent and future growth prospects, among other growth strategies used by key players to stay ahead of the game. Additionally, recent trends, mergers and acquisitions, region-wise growth analysis along with challenges that are affecting the growth of the market are also stated in the report.
The market in North America region is anticipated to observe a vibrant growth during the 2020-2028 period. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The increasing initiatives taken by various research institutes and organizations for improving medical facilities and services are further leading to the market growth. The Centers for Disease Control and Prevention, a prominent public health institute of the United States, provided grant funding for a large number of healthcare initiatives in the region in 2018. The initiative such as vaccines for children and chronic disease prevention & health promotion received the highest portion of resources with 50.87% and 10.07% of a total of USD 7,496,307,789 respectively. This was followed by HIV/AIDS, viral Hepatitis, STI & TB prevention which received 9.82% as well as injury prevention and control with 5.66% of the funds. The growing number of health disorders and rising demand for improved treatment and preventive measures have led to the technological advancements in the medical industry.
Click to Download Sample Report@
In Q4 2021, U.S. current-account deficit widened stood at $224.8 billion. However, in Q1 22, CAD rose by 29.6%, reached to $291.4 billion, adding $66.6 billion to the gap. Export of good and services increased by $25.7 billion to reach $1.03 trillion in the first quarter of 2022. However, country's goods and services deficit was $79.6 billion in June, down $5.3 billion from $84.9 billion in May, revised- reflecting some sight of relief. On the other hand, annual inflation rate in the country hit 8.5%. Energy CPI surged by 32.9% in July 2022, inflating the cost of logistic and signs to disrupt supply chain whilst electricity cost upsurged by 15.2%, highest since Feb 2006. Apart from that, In July 2022, existing US home sales declined 5.9% to 4.81 million (seasonally adjusted annual rate), the lowest since May of 2020 and below market expectations of 4.89 million. As mortgage rate touches highest at 6%, sales for houses declined for a sixth consecutive month. Global energy crises to remain at focal point impacting the economic activity in the U.S, pushing consumers to spend less on the products and services and save more.
On the other hand, the worst is expected to be seen in the European countries, especially during 2022 winters. The energy and gas crises has already started grappling the region, wherein many Western European countries including Germany is looking for coal fired solutions to tackle the gas supply shortage created by Russian-Ukraine conflict.
Amidst global concerns, market players have started looking for safe investments by holding on to the new technology and product launches. Factors like currency translation, disruption in global supply chain, Anti-China sentiments brewing across the globe, slowdown in Chinese economy, inflated products prices, USD getting stronger every week, decreasing purchasing power and strict measures taken by central banks/institutions across the world to ensure less spending and more saving, could hit the demand for the product and service badly in near future.
Healthcare Companies and Private Service Providers to have a minimal damage Caused by Inflation:
As US govt. remains committed to quality by spending more in the Medicaid and Medicare programs, incentives by govt. to medical devices, pharma companies and biotech to benefit the market players in short and long term goals. In 2021, U.S. spent $12,318/person on healthcare- highest amongst all OECD countries followed by Germany at $7,383. The federal government commitment towards healthcare systems to enable market players expanding their revenues and mitigating the risk posed by the inflation.
On account of growing personal expenditure on healthcare in the United States, the healthcare industry in the region is developing at a rapid pace, thereby resulting in the growth of the North America Sly Syndrome Market . The personal healthcare expenditure in the country has witnessed a significant increase in the past decade from USD 1,804 Billion in 2006 to USD 2,834 Billion in 2016, which resulted in an average annual percent change of 4.6% during this period as reported by CDC. Hospital expenses accounted for the highest share with 38.2% of the total personal healthcare expenditure in United States in 2016. This was followed by physician & clinical, prescription drugs and dental expenses which held 23.5%, 11.6% and 4.4% share respectively. The inclination of the population to spend in this industry in exchange for enhanced technologies and advanced treatment methods as well as dental and hospital care is estimated to give rise to the growth of North America Sly Syndrome Market in the North America region by the end of 2028.
Click To Download Table of Contents Of This Report:
Furthermore, to provide better understanding of internal and external marketing factors, the multi-dimensional analytical tools such as SWOT and PESTEL analysis have been implemented in the report. Moreover, the report consists of market segmentation, CAGR (Compound Annual Growth Rate), BPS analysis, Y-o-Y growth (%), Porter's five forces analysis, absolute $ opportunity and anticipated cost structure of the market.
CRIFAX is driven by integrity and commitment to its clients, and provides cutting-edge marketing research and consulting solutions with a step-by-step guide to accomplish their business prospects. With the help of our industry experts having hands on experience in their respective domains, we make sure that our industry enthusiasts understand all the business aspects relating to their projects, which further improves the consumer base and the size of their organization. We offer wide range of unique marketing research solutions ranging from customized and syndicated research reports to consulting services, out of which, we update our syndicated research reports annually to make sure that they are modified according to the latest and ever-changing technology and industry insights. This has helped us to carve a niche in delivering 'distinctive business services' that enhanced our global clients' trust in our insights, and helped us to outpace our competitors as well.
U.K. Phone: +44 161 394 2021
U.S. Phone: +1 917 924 8284
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.